Expanded Access Program With Nivolumab to Treat Melanoma
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT02142218
- Status
- No Longer Available
Conditions
- Stage III (Unresectable) or Stage IV Advanced Melanoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUG
Study Details
The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.
Key Dates
- First listed
- May 20, 2014
- Start date
- Jun 30, 2014
- Status verified
- Sep 2016
- Primary completion
- May 31, 2018
- Completion
- May 31, 2018